"Ct"

Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.

Nowadays, brain tumor is one of the common diseases, so it is necessary for us to learn more about it. What are the physical manifestations?

The production of dampness is closely related to poor living and eating habits, so to get rid of dampness at the root, you must develop good eating and living habits. So, how to get rid of dampness most effectively?

Fujifilm Corporation and the National Center for Psychiatric and Neurological Research have announced positive research results using Fujifilm's new AI technology to predict whether a patient with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) within two years.

In today's rapidly changing world of science and technology, a research result that sounds very sci-fi will appear from time to time. No, a paper published in the journal Science Robotics belongs to this scope: a cell regeneration robot that successfully works in vivo.

A new study has found that Istradefylline, a drug already approved to treat Parkinson's disease, not only reduces the toxicity associated with the chemotherapy drug cisplatin, but also boosts its cancer-fighting power, promising a potential treatment to reduce the side effects of chemotherapy.

There are many ways to treat prostate cancer and radiation therapy is a common treatment for prostate cancer, but many prostate cancer patients want to know what the side effects of radiation therapy are.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

New research by japanese scientists has found that

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.